Bruce E. Johnson

TL;DR: The results suggest that the LOH11B region contains a gene responsible for a more malignant phenotype independent of the metastatic potential of lung cancer and suggest that alterations in this gene are associated with cigarette consumption and are more frequent in men than in women.

TL;DR: The results of the KEYNOTE-024 trial show therapeutic benefits for the checkpoint inhibitor pembrolizumab for the subset of patients with non–small-cell lung cancer (NSCLC) who have a high level of programmed death ligand 1 (PD-L1) expression.

TL;DR: The Fourth Cambridge Conference on Novel Agents in the Treatment of Lung Cancer was held in Cambridge, Massachusetts on September 29 to 30, 2006, to discuss ongoing clinical research of novel targeted agents for the treatment of non–small cell lung cancer, along with supportive basic and translational research into the molecular pathways implicated in cancer growth and resistance.

TL;DR: This study reframes the transcriptional taxonomy of PDAC, demonstrates how divergent transcriptional subtypes associate with unique tumor microenvironments, and highlights the importance of evaluating both genotype and transcriptional phenotype to establish high-fidelity patient-derived cancer models.

TL;DR: In this paper , the authors evaluated the impact of the pandemic on clinical trial conduct by assessing the enrollment on, accrual to, and activation of oncology therapeutic clinical trials at two large academic centers in the United States between December 2019 and June 2021.